EDIT News and Press, Editas Medicine Inc. From 07/24/23

CAMBRIDGE, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linda C. Burkly, Ph.D., as the Company’s Executive Vice President and Chief Scientific Officer. Dr. Burkly will lead Editas&...

2023-07-23 08:29:06 ET Summary The progress of EDIT-301 in Phase 1/2 RUBY and EdiTHAL studies is encouraging. I am increasingly turning more bearish on EDIT due to increased competition and a less attractive financial outlook. The focus now is on year-end catalysts and increas...

2023-07-14 17:40:11 ET Summary Editas Medicine reported promising initial results from the EDIT-301 trials for inherited blood disorders, leading to a rating upgrade to "outperform" by Raymond James. The company's financial standing was strengthened by a $125 million share offerin...

2023-07-12 10:45:16 ET Summary bluebird works as a biotech company developing curative gene therapies to save lives. Concerns over its cash runway and clinical trials are overblown, with the stock near all-time lows. Near-term catalysts from Lovo-cell, Zynteglo, and Skysona ar...

2023-06-29 09:53:00 ET What do CRISPR Therapeutics (NASDAQ: CRSP) , Bluebird Bio (NASDAQ: BLUE) , Editas Medicine (NASDAQ: EDIT) , and Intellia Therapeutics (NASDAQ: NTLA) all have in common? If you said, "They're biotechs developing gene therapies," you're r...

2023-06-20 10:23:00 ET On June 15, Editas Medicine (NASDAQ: EDIT) saw its shares collapse by 15% after announcing it would be issuing new stock to raise approximately $125 million. The biotech will almost certainly use the funds to continue advancing gene-therapy candidates through ...

2023-06-15 10:06:53 ET Gainers: Aldeyra Therapeutics ( ALDX ) +11% . Bioventus ( BVS ) +11% . IO Biotech ( IOBT ) +11% . Verastem ( VSTM ) +10% . Zentalis Pharmaceuticals ( ZNTL ) +9% . Losers: Mersana Therapeutics ( MRSN...

2023-06-15 10:00:00 ET A short squeeze can generate outsize returns on capital in a hurry. This process, defined as a flood of short covering following a sharp uptick in a stock's price, can turn into a runaway positive feedback loop, sparking a parabolic upturn in a company's share price. ...

2023-06-15 08:24:35 ET Mersana Therapeutics ( MRSN ) -67% on FDA partial hold on trials for lead asset. Bone Biologics Corporation ( BBLG ) -53% on offering prices of $5M . Gambling.com Group Limited ( GAMB ) -15% launches secondary offering of 4....

2023-06-15 04:46:16 ET A clinical-stage genome editing company- Editas Medicine ( NASDAQ: EDIT ) prices 12.5M shares at $10.00 per share. Gross proceeds are expected to be ~$125M. Underwriters have a 30-day option to purchase up to an additional 1.88M shares. The o...